can you feel it, page-22

spicer's right, get into SLA for the right reasons- this is a $50m
company that in a year will be making $50-100m profit. i do think
there will be small dividends before 2012 to keep the natives from
getting restless.

by 2012-2013 all the main development will be paid for (big tomsk factory,
a factory in NW USA, new applications trials for ropren like alzheimers, nano delivery, all the other current bioeffectives coming into commercialisation, new
bioeffectives getting researched and patented), then its a couple of bucks
dividend every year thereafter. and if not several $ div per year per
share then it will be $ per share per year of retained profits to buy
other companies.

You're buying the next CSL people, and not at govt-float prices. CSL
has 600m shares to SLA's 200m, today they sell for $34 not 34c,
and SLA's products are about as important to human health as CSL's
(maybe not ropren for livers, but if these early indications of product
extension to eg alzheimers pan out then SLA will be bigger than CSL)

the majority of the risk attached to any biotech is in the research phase
and ropren has completed that (to russian standards at least, and that
is the only standard that matters for now).